DE60326833D1 - Vitamin-mitomycin-konjugate - Google Patents
Vitamin-mitomycin-konjugateInfo
- Publication number
- DE60326833D1 DE60326833D1 DE60326833T DE60326833T DE60326833D1 DE 60326833 D1 DE60326833 D1 DE 60326833D1 DE 60326833 T DE60326833 T DE 60326833T DE 60326833 T DE60326833 T DE 60326833T DE 60326833 D1 DE60326833 D1 DE 60326833D1
- Authority
- DE
- Germany
- Prior art keywords
- conjugates
- group
- folate
- mitomycin
- pathogenic cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38057902P | 2002-05-15 | 2002-05-15 | |
| US42591802P | 2002-11-13 | 2002-11-13 | |
| PCT/US2003/014969 WO2003097647A1 (en) | 2002-05-15 | 2003-05-13 | Vitamin-mitomycin conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60326833D1 true DE60326833D1 (de) | 2009-05-07 |
Family
ID=29553501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60326833T Expired - Lifetime DE60326833D1 (de) | 2002-05-15 | 2003-05-13 | Vitamin-mitomycin-konjugate |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7910594B2 (de) |
| EP (2) | EP1504010B1 (de) |
| JP (1) | JP4814520B2 (de) |
| KR (1) | KR20040106547A (de) |
| AT (1) | ATE426414T1 (de) |
| AU (1) | AU2003243226A1 (de) |
| CA (1) | CA2484640C (de) |
| DE (1) | DE60326833D1 (de) |
| ES (1) | ES2324708T3 (de) |
| WO (1) | WO2003097647A1 (de) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1389209B1 (de) * | 2001-04-24 | 2009-04-08 | Purdue Research Foundation | Folat-mimetika und deren folatrezeptorbindende konjugate |
| US7910594B2 (en) | 2002-05-15 | 2011-03-22 | Endocyte, Inc. | Vitamin-mitomycin conjugates |
| EP2517730A3 (de) * | 2003-01-27 | 2013-01-02 | Endocyte, Inc. | Vitaminrezeptorbindende Wirkstofffreisetzungskonjugate |
| CN101239190B (zh) * | 2003-01-27 | 2013-09-25 | 恩多塞特公司 | 维生素受体结合递药缀合物 |
| CN101098854B (zh) | 2004-07-23 | 2012-12-05 | 恩多塞特公司 | 二价连接体及其轭合物 |
| US20120269886A1 (en) | 2004-12-22 | 2012-10-25 | Nitto Denko Corporation | Therapeutic agent for pulmonary fibrosis |
| JP2009221164A (ja) | 2008-03-17 | 2009-10-01 | Nitto Denko Corp | 肺線維症処置剤 |
| PT2730277T (pt) | 2004-12-22 | 2020-04-21 | Nitto Denko Corp | Veículo de fármaco e kit de veículo de fármaco para a inibição da fibrose |
| CN101175757B (zh) * | 2005-03-16 | 2012-11-14 | 恩多塞特公司 | 蝶酸及其缀合物的合成和纯化 |
| CA2602585A1 (en) | 2005-03-30 | 2006-10-05 | Purdue Research Foundation | Method for cancer prognosis using cellular folate vitamin receptor quantification |
| EP1948240A2 (de) * | 2005-08-19 | 2008-07-30 | Endocyte, Inc. | Liganden-konjugate von vinca-alkaloiden, analoga und derivaten |
| CN103893779A (zh) * | 2005-08-19 | 2014-07-02 | 恩多塞特公司 | 多药物配体缀合物 |
| US9572886B2 (en) | 2005-12-22 | 2017-02-21 | Nitto Denko Corporation | Agent for treating myelofibrosis |
| EP1832575A1 (de) | 2006-03-06 | 2007-09-12 | Sulfidris S.r.l. | Entzündungshemmende Mittel |
| WO2008101231A2 (en) * | 2007-02-16 | 2008-08-21 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
| AU2008224988A1 (en) | 2007-03-14 | 2008-09-18 | Endocyte, Inc. | Binding ligand linked drug delivery conjugates of tubulysins |
| TWI407971B (zh) * | 2007-03-30 | 2013-09-11 | Nitto Denko Corp | Cancer cells and tumor-related fibroblasts |
| AU2008268432B2 (en) | 2007-06-25 | 2015-01-15 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
| US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
| PT2187965T (pt) | 2007-08-17 | 2020-01-17 | Purdue Research Foundation | Conjugados ligando-ligante de ligação a psma e métodos para utilização |
| JP2010539245A (ja) | 2007-09-14 | 2010-12-16 | 日東電工株式会社 | 薬物担体 |
| WO2009055562A1 (en) | 2007-10-25 | 2009-04-30 | Endocyte, Inc. | Tubulysins and processes for preparing |
| US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
| JP5950428B2 (ja) | 2010-08-05 | 2016-07-13 | 日東電工株式会社 | 線維化組織から正常組織を再生するための組成物 |
| BR112013011590A2 (pt) * | 2010-11-12 | 2019-09-24 | Endocyte Inc | método de tratamento de câncer |
| US10080805B2 (en) | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
| US9629918B2 (en) | 2012-02-29 | 2017-04-25 | Purdue Research Foundation | Folate receptor alpha binding ligands |
| US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
| SG11201502896XA (en) | 2012-10-16 | 2015-05-28 | Endocyte Inc | Drug delivery conjugates containing unnatural amino acids and methods for using |
| JP6892218B2 (ja) | 2012-11-15 | 2021-06-23 | エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． | 薬物送達結合体およびｐｓｍａ発現細胞によって引き起こされる疾患の治療方法 |
| JP6133431B2 (ja) | 2012-11-24 | 2017-05-24 | ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． | 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用 |
| JP6340162B2 (ja) | 2012-12-20 | 2018-06-06 | 日東電工株式会社 | アポトーシス誘導剤 |
| EP3415489A1 (de) | 2013-10-18 | 2018-12-19 | Deutsches Krebsforschungszentrum | Markierte inhibitoren des prostataspezifischen membranantigens (psma), deren verwendung als kontrastmittel und pharmazeutika zur behandlung von prostatakrebs |
| PT3122757T (pt) | 2014-02-28 | 2023-11-03 | Hangzhou Dac Biotech Co Ltd | Ligantes carregados e as suas utilizações em conjugação |
| EP3127915B1 (de) | 2014-04-02 | 2020-08-26 | Nitto Denko Corporation | Von rbp-abstammendes zielmolekül und verwendung davon |
| CA2943733C (en) | 2014-04-07 | 2022-03-01 | Nitto Denko Corporation | Polymer-based hydrotropes for hydrophobic drug delivery |
| US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
| CA2985330A1 (en) * | 2015-03-17 | 2016-09-22 | Lipomedix Pharmaceuticals Ltd. | Methods for the treatment of bladder cancer |
| BR112017020689A2 (pt) | 2015-04-07 | 2018-06-26 | Univ Cornell | imunoconjugados em nanopartículas |
| US10406238B2 (en) | 2015-05-11 | 2019-09-10 | Purdue Research Foundation | Ligand ionophore conjugates |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2515483A (en) | 1946-08-10 | 1950-07-18 | Merck & Co Inc | Diacylated pteroic acid and process for preparing same |
| US2816110A (en) | 1956-11-23 | 1957-12-10 | Merck & Co Inc | Methods for the production of substituted pteridines |
| US3392173A (en) | 1964-03-09 | 1968-07-09 | Lilly Co Eli | Novel acyl derivatives of desacetyl-vincaleukoblastine and processes for their preparation |
| US3387001A (en) | 1964-10-19 | 1968-06-04 | Lilly Co Eli | Novel aminoacyl esters of desacetyl vincaleukoblastine |
| US4203898A (en) | 1977-08-29 | 1980-05-20 | Eli Lilly And Company | Amide derivatives of VLB, leurosidine, leurocristine and related dimeric alkaloids |
| US4166810A (en) | 1978-04-20 | 1979-09-04 | Eli Lilly And Company | Derivatives of 4-desacetyl VLB C-3 carboxyhydrazide |
| US4337339A (en) | 1979-04-30 | 1982-06-29 | Baker Instruments Corp. | Process for preparation of folic acid derivatives |
| US4713249A (en) | 1981-11-12 | 1987-12-15 | Schroeder Ulf | Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof |
| US5140104A (en) | 1982-03-09 | 1992-08-18 | Cytogen Corporation | Amine derivatives of folic acid analogs |
| EP0116208B1 (de) | 1982-12-07 | 1988-03-30 | Kyowa Hakko Kogyo Co., Ltd. | Mitomycin-Analoge |
| JPS59175493A (ja) | 1983-03-25 | 1984-10-04 | Kyowa Hakko Kogyo Co Ltd | マイトマイシン誘導体 |
| US4866180A (en) | 1984-02-24 | 1989-09-12 | Bristol-Myers Company | Amino disulfide thiol exchange products |
| JPS60255789A (ja) | 1984-06-01 | 1985-12-17 | Kyowa Hakko Kogyo Co Ltd | マイトマイシン誘導体，その製造法および抗腫瘍剤 |
| US5266333A (en) | 1985-03-06 | 1993-11-30 | American Cyanamid Company | Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone |
| IL82579A0 (en) | 1986-05-27 | 1987-11-30 | Lilly Co Eli | Immunoglobulin conjugates |
| US4801688A (en) | 1986-05-27 | 1989-01-31 | Eli Lilly And Company | Hydrazone immunoglobulin conjugates |
| US5103018A (en) | 1986-08-26 | 1992-04-07 | Kyowa Hakko Kogyo Kabushiki Kaisha | Mitomycin derivatives |
| US5006652A (en) | 1988-08-08 | 1991-04-09 | Eli Lilly And Company | Intermediates for antibody-vinca drug conjugates |
| US5094849A (en) | 1988-08-08 | 1992-03-10 | Eli Lilly And Company | Cytotoxic antibody conjugates of hydrazide derivatized vinca analogs via simple organic linkers |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5688488A (en) | 1989-04-03 | 1997-11-18 | Purdue Research Foundation | Composition and method for tumor imaging |
| WO1991007418A1 (en) | 1989-11-13 | 1991-05-30 | Xoma Corporation | Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen |
| US5998603A (en) | 1994-09-29 | 1999-12-07 | Isis Pharmaceuticals, Inc. | 4'-desmethyl nucleoside analogs, and oligomers thereof |
| DE69132925T2 (de) | 1990-08-29 | 2002-10-10 | Ct Hospitalier Regional De Nan | An stabile proteinkernstruktur gebundene proteinpolyliganden |
| US6335434B1 (en) | 1998-06-16 | 2002-01-01 | Isis Pharmaceuticals, Inc., | Nucleosidic and non-nucleosidic folate conjugates |
| US5159079A (en) | 1991-12-20 | 1992-10-27 | Eli Lilly And Company | 2-piperidones as intermediates for 5-deaza-10-oxo- and 5-deaza-10-thio-5,6,7,8-tetrahydrofolic acids |
| US6004555A (en) | 1992-03-05 | 1999-12-21 | Board Of Regents, The University Of Texas System | Methods for the specific coagulation of vasculature |
| WO1994025022A1 (en) | 1993-04-23 | 1994-11-10 | Abbott Laboratories | Rapamycin conjugates and antibodies |
| US5417982A (en) | 1994-02-17 | 1995-05-23 | Modi; Pankaj | Controlled release of drugs or hormones in biodegradable polymer microspheres |
| IL112873A (en) | 1994-03-08 | 2005-03-20 | Wyeth Corp | Rapamycin-fkbp12 binding proteins, their isolation and their use |
| US6171859B1 (en) | 1994-03-30 | 2001-01-09 | Mitokor | Method of targeting conjugate molecules to mitochondria |
| US5547668A (en) | 1995-05-05 | 1996-08-20 | The Board Of Trustees Of The University Of Illinois | Conjugates of folate anti-effector cell antibodies |
| US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
| US6030941A (en) | 1996-05-01 | 2000-02-29 | Avi Biopharma, Inc. | Polymer composition for delivering substances in living organisms |
| CA2253904A1 (en) | 1996-05-03 | 1997-11-13 | Immunomedics, Inc. | Targeted combination immunotherapy of cancer |
| DE19621133A1 (de) | 1996-05-24 | 1997-11-27 | Boehringer Mannheim Gmbh | Bestimmungsverfahren mit oligomerisierten Rezeptoren |
| EP0926955A4 (de) | 1996-09-12 | 2003-05-07 | Merck & Co Inc | Konjugate nützlich in die behandlung von prostatakarzinom |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| US6071532A (en) | 1996-10-15 | 2000-06-06 | Emory University | Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof |
| US6177404B1 (en) | 1996-10-15 | 2001-01-23 | Merck & Co., Inc. | Conjugates useful in the treatment of benign prostatic hyperplasia |
| WO1999020626A1 (en) | 1997-10-17 | 1999-04-29 | Purdue Research Foundation | Folic acid derivatives |
| GB9723669D0 (en) | 1997-11-07 | 1998-01-07 | Univ Aberdeen | Skin penetration enhancing components |
| US6380395B1 (en) | 1998-04-21 | 2002-04-30 | Bristol-Myers Squibb Company | 12, 13-cyclopropane epothilone derivatives |
| US6093382A (en) | 1998-05-16 | 2000-07-25 | Bracco Research Usa Inc. | Metal complexes derivatized with folate for use in diagnostic and therapeutic applications |
| US6291684B1 (en) | 1999-03-29 | 2001-09-18 | Bristol-Myers Squibb Company | Process for the preparation of aziridinyl epothilones from oxiranyl epothilones |
| CA2369595C (en) * | 1999-04-23 | 2010-10-05 | Alza Corporation | Conjugate having a cleavable linkage for use in a liposome |
| AUPQ014799A0 (en) | 1999-05-04 | 1999-05-27 | Access Pharmaceuticals Australia Pty Limited | Amplification of folate-mediated targeting to tumor cells using polymers |
| AUPQ071299A0 (en) * | 1999-06-02 | 1999-06-24 | Access Pharmaceuticals Australia Pty Limited | Vitamin directed dual targeting therapy |
| JP2003512338A (ja) | 1999-10-15 | 2003-04-02 | メイオウ・フアウンデーシヨン・フオー・メデイカル・エジユケイシヨン・アンド・リサーチ | 造影剤および抗腫瘍薬として有用なコバラミン結合体 |
| US7067111B1 (en) | 1999-10-25 | 2006-06-27 | Board Of Regents, University Of Texas System | Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging |
| AU5697001A (en) * | 2000-03-31 | 2001-10-15 | Purdue Research Foundation | Method of treatment using ligand-immunogen conjugates |
| US6670355B2 (en) | 2000-06-16 | 2003-12-30 | Wyeth | Method of treating cardiovascular disease |
| US6511986B2 (en) | 2000-08-11 | 2003-01-28 | Wyeth | Method of treating estrogen receptor positive carcinoma |
| WO2002024706A2 (en) | 2000-09-19 | 2002-03-28 | Wyeth | Water soluble rapamycin esters |
| US6399625B1 (en) | 2000-09-27 | 2002-06-04 | Wyeth | 1-oxorapamycins |
| US6399626B1 (en) | 2000-10-02 | 2002-06-04 | Wyeth | Hydroxyesters of 7-desmethylrapamycin |
| US6440991B1 (en) | 2000-10-02 | 2002-08-27 | Wyeth | Ethers of 7-desmethlrapamycin |
| US6821731B2 (en) | 2000-11-28 | 2004-11-23 | Wyeth | Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis of prostate cancer |
| AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
| MXPA03008959A (es) | 2001-04-02 | 2004-10-15 | Wyeth Corp | Pd-1, un receptor para b7-4 y sus usos. |
| EP1389209B1 (de) | 2001-04-24 | 2009-04-08 | Purdue Research Foundation | Folat-mimetika und deren folatrezeptorbindende konjugate |
| US7109165B2 (en) | 2001-05-18 | 2006-09-19 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| MXPA03010909A (es) | 2001-06-01 | 2004-02-17 | Bristol Myers Squibb Co | Derivados de epotilona. |
| US20040018203A1 (en) | 2001-06-08 | 2004-01-29 | Ira Pastan | Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates |
| JP2005501052A (ja) * | 2001-07-31 | 2005-01-13 | イムノメディクス， インコーポレイテッド | ポリマー送達系 |
| UA77200C2 (en) | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
| JP2005501868A (ja) | 2001-08-22 | 2005-01-20 | ワイス | ラパマイシン２９−エノール |
| WO2003018574A1 (en) | 2001-08-22 | 2003-03-06 | Wyeth | Rapamycin dialdehydes |
| DE60234782D1 (de) | 2001-09-28 | 2010-01-28 | Purdue Research Foundation | Behandlungsverfahren mit liganden-immunogenkonjugaten |
| JP5021152B2 (ja) * | 2001-10-22 | 2012-09-05 | ザ スクリプス リサーチ インスティチュート | インテグリンターゲッティング化合物 |
| GR1004163B (el) | 2001-11-01 | 2003-02-21 | Πολυκυκλικα παραγωγα τροποποιησης των οπτικων ιδιοτητων και των ιδιοτητων αντοχης στο πλασμα των πολυμερων λιθογραφιας | |
| US8043602B2 (en) | 2002-02-07 | 2011-10-25 | Endocyte, Inc. | Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology |
| US7000695B2 (en) | 2002-05-02 | 2006-02-21 | Halliburton Energy Services, Inc. | Expanding wellbore junction |
| NZ536467A (en) | 2002-05-06 | 2006-11-30 | Endocyte Inc | Vitamin-targeted imaging agents |
| US6596757B1 (en) | 2002-05-14 | 2003-07-22 | Immunogen Inc. | Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use |
| US7910594B2 (en) | 2002-05-15 | 2011-03-22 | Endocyte, Inc. | Vitamin-mitomycin conjugates |
| AU2003266233A1 (en) | 2002-07-09 | 2004-01-23 | Morphochem Aktiengesellschaft Fur Kombinatorische Chemie | Novel tubulysin analogues |
| WO2004032877A2 (en) | 2002-10-10 | 2004-04-22 | Wyeth | Compositions, organisms and methodologies employing a novel human kinase |
| JP2006516388A (ja) | 2002-11-21 | 2006-07-06 | ワイス | ループス腎炎の治療用組成物および方法 |
| DE10254439A1 (de) | 2002-11-21 | 2004-06-03 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Tubulysine, Herstellungsverfahren und Tubulysin-Mittel |
| EP2517730A3 (de) | 2003-01-27 | 2013-01-02 | Endocyte, Inc. | Vitaminrezeptorbindende Wirkstofffreisetzungskonjugate |
| AR042938A1 (es) | 2003-02-06 | 2005-07-06 | Wyeth Corp | Uso del cci-779 en el tratamiento de la fibrosis hepatica |
| WO2004094595A2 (en) | 2003-04-17 | 2004-11-04 | Alnylam Pharmaceuticals Inc. | MODIFIED iRNA AGENTS |
| WO2004101803A2 (en) | 2003-05-12 | 2004-11-25 | Wyeth Holdings Corporation | Process for producing anticancer agent ll-d45042 |
| AU2004259669A1 (en) | 2003-07-16 | 2005-02-03 | Wyeth | CCI-779 Isomer C |
| UA83245C2 (en) | 2003-08-07 | 2008-06-25 | Уайт | Regioselective synthesis of cci-779 |
| AU2005272816B2 (en) | 2004-08-10 | 2011-08-11 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides |
| US7290958B2 (en) | 2004-12-03 | 2007-11-06 | Airfield Systems, Llc | Subsurface drainage system and drain structure therefor |
| CA2602585A1 (en) | 2005-03-30 | 2006-10-05 | Purdue Research Foundation | Method for cancer prognosis using cellular folate vitamin receptor quantification |
| JP5175723B2 (ja) | 2005-07-05 | 2013-04-03 | パーデュー・リサーチ・ファウンデーション | 単球介在性疾患を治療するための組成物の調製 |
| PE20080102A1 (es) | 2006-05-25 | 2008-02-11 | Bristol Myers Squibb Co | Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos |
| WO2008101231A2 (en) | 2007-02-16 | 2008-08-21 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
-
2003
- 2003-05-13 US US10/513,372 patent/US7910594B2/en not_active Expired - Fee Related
- 2003-05-13 WO PCT/US2003/014969 patent/WO2003097647A1/en active Application Filing
- 2003-05-13 EP EP03752681A patent/EP1504010B1/de not_active Expired - Lifetime
- 2003-05-13 AU AU2003243226A patent/AU2003243226A1/en not_active Abandoned
- 2003-05-13 DE DE60326833T patent/DE60326833D1/de not_active Expired - Lifetime
- 2003-05-13 ES ES03752681T patent/ES2324708T3/es not_active Expired - Lifetime
- 2003-05-13 KR KR10-2004-7018375A patent/KR20040106547A/ko not_active Application Discontinuation
- 2003-05-13 AT AT03752681T patent/ATE426414T1/de not_active IP Right Cessation
- 2003-05-13 CA CA2484640A patent/CA2484640C/en not_active Expired - Fee Related
- 2003-05-13 JP JP2004505379A patent/JP4814520B2/ja not_active Expired - Fee Related
- 2003-05-13 EP EP09002632A patent/EP2060272A3/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP1504010A1 (de) | 2005-02-09 |
| WO2003097647A1 (en) | 2003-11-27 |
| ATE426414T1 (de) | 2009-04-15 |
| CA2484640A1 (en) | 2003-11-27 |
| EP1504010A4 (de) | 2007-03-28 |
| JP4814520B2 (ja) | 2011-11-16 |
| KR20040106547A (ko) | 2004-12-17 |
| EP1504010B1 (de) | 2009-03-25 |
| JP2005531564A (ja) | 2005-10-20 |
| CA2484640C (en) | 2012-01-17 |
| US7910594B2 (en) | 2011-03-22 |
| AU2003243226A1 (en) | 2003-12-02 |
| US20050165227A1 (en) | 2005-07-28 |
| EP2060272A2 (de) | 2009-05-20 |
| ES2324708T3 (es) | 2009-08-13 |
| EP2060272A3 (de) | 2009-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60326833D1 (de) | Vitamin-mitomycin-konjugate | |
| UA93043C2 (ru) | ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ ДЛЯ ПОЛУЧЕНИЯ ТРАНС-5-ХЛОР-2-МЕТИЛ-2,3,3А,12В-ТЕТРАГИДРО-1Н-ДИБЕНЗ[2,3:6,7]ОКСЕПИНО[4,5-с]ПИРОЛА | |
| CR8254A (es) | [1,8] naftidrin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia | |
| NO20084752L (no) | Konjugater av aziridinayl-epotilonanaloger og farmasoytiske sammensetninger som inneholder disse | |
| ZA200707901B (en) | Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same | |
| GT200100214A (es) | Inhibidores de metaloproteinasa del tipo pirimidin-2,4,6-triona | |
| RS20080128A (en) | Hydroxy substituted 1h-imidazopyridines and methods | |
| EA200601160A1 (ru) | 2,6-бисгетероарил-4-аминопиримидины в качестве антагонистов аденозиновых рецепторов | |
| CY1109558T1 (el) | Παραγωγα βενζο[d]αζεπινης για την θεραπεια νευρολογικων διαταραχων | |
| ECSP066311A (es) | Derivados de la piperazina y su uso como agentes terapéuticos | |
| UY29700A1 (es) | "8-(3-amino-piperidin-1-il)-xantinas, su preparación y su uso como medicamentos | |
| ECSP088413A (es) | Preparación y uso de derivados de tetrahidropirrolo[3,2-c]piridin-4-ona para el tratamiento de la obesidad, trastornos psiquiátricos y neurológicos | |
| WO2007046867A3 (en) | Piperidine derivatives and their uses as therapeutic agents | |
| DE60029944D1 (de) | Polyamine und ihre therapeutische verwendung | |
| WO2007005941A3 (en) | Liver targeted conjugates | |
| WO2003045319A3 (en) | Targeted therapeutics and uses thereof | |
| BR0313385A (pt) | Derivados de pirimidina-2,4-diona como inibidores de metaloproteinase da matriz | |
| BRPI0418255A (pt) | derivados de piperazina e piperidina n-substituìdos | |
| WO2003026563A3 (en) | Conjugated anti-psychotic drugs and uses thereof | |
| MA31630B1 (fr) | Dérivés de 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamides et de 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazépine-7-carboxamides, leur préparation et leur application en thérapeutique | |
| CR9058A (es) | Derivados de indol como inhibidores de la adenilato ciclasa soluble | |
| UA86873C2 (en) | SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES | |
| WO2005082457A3 (fr) | Utilisation de derives d’indolizine 1,2,3 substitues pour le traitement de maladies liees à une angiogenese pathologique choroïdienne. | |
| MY140858A (en) | Ampa receptor potentiators | |
| WO2005097757A3 (en) | Nucleoside derivatives and therapeutic use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |